Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | HTT | P42858 | 3/20 | 0.61 |
| ▸ | PKM | P14618 | 2/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.59 |
| ▸ | HPGDS | O60760 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.52 |
| ▸ | THPO | P40225 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 4/20 | 0.51 |
| ▸ | JAK1 | P23458 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL797230 | 1.00 | LMNA (0.61) | LMNAHTTPKMHSD17B10PAK1 | |
| SCHEMBL5452621 | 0.98 | LMNA (0.60) | LMNAHTTPKMHSD17B10PAK1 | |
| SCHEMBL9205078 | 0.95 | LMNA (0.56) | LMNAHTTPKMHSD17B10PAK1 | |
| SCHEMBL797545 | 0.92 | LMNA (0.51) | LMNAHTTPKMHSD17B10PAK1 | |
| SCHEMBL30473749 | 0.92 | LMNA (0.51) | LMNAHTTPKMHSD17B10PAK1 | |
| SCHEMBL5670409 | 0.86 | RPS6KB1 (0.48) | LMNAHTTPKMHSD17B10PAK1 | |
| Hydrochloric Acid SCHEMBL1748687 | 0.84 | RPS6KB1 (0.47) | LMNAHTTPKMHSD17B10PAK1 | |
| SCHEMBL797050 | 0.80 | CHUK (0.52) | LMNAHTTPKMHSD17B10PAK1 | |
| SCHEMBL7621597 | 0.78 | CHUK (0.50) | LMNAHTTPKMHSD17B10PAK1 | |
| SCHEMBL2031719 | 0.77 | JAK2 (0.52) | LMNAHTTPKMHSD17B10PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007025090-A2 | HETEROBICYCLIC AND - TRICYCLIC INHIBITORS OF MAPK/ERK KINASE | KALYPSYS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070049591-A1 | Inhibitors of MAPK/Erk Kinase | KALYPSYS, INC. | 2007-03-01 | — | — | US | disclosed |
| US-20070049591-A1 | Inhibitors of MAPK/Erk Kinase | KALYPSYS, INC. | 2007-03-01 | — | — | US | disclosed |
| US-20070049591-A1 | Inhibitors of MAPK/Erk Kinase | KALYPSYS, INC. | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049591-A1 | Inhibitors of MAPK/Erk Kinase | MAPK1, MAP3K1, MAP3K6 | LMNA 2209/4885HTT 3149/4885PKM 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.